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Meropenem versus piperacillin-tazobactam for definitive treatment of
bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and
Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial
Abstract
Background Gram-negative bacteria such as Escherichia coli or Klebsiella spp. frequently cause
bloodstream infections. There has been a worldwide increase in resistance in these species to antibiotics
such as third generation cephalosporins, largely driven by the acquisition of extended-spectrum betalactamase or plasmid-mediated AmpC enzymes. Carbapenems have been considered the most effective
therapy for serious infections caused by such resistant bacteria; however, increased use creates selection
pressure for carbapenem resistance, an emerging threat arising predominantly from the dissemination of
genes encoding carbapenemases. Recent retrospective data suggest that beta-lactam/beta-lactamase
inhibitor combinations, such as piperacillin-tazobactam, may be non-inferior to carbapenems for the
treatment of bloodstream infection caused by extended-spectrum beta-lactamase-producers, if
susceptible in vitro. This study aims to test this hypothesis in an effort to define carbapenem-sparing
alternatives for these infections. Methods/Design The study will use a multicentre randomised controlled
open-label non-inferiority trial design comparing two treatments, meropenem (standard arm) and
piperacillin-tazobactam (carbapenem-sparing arm) in adult patients with bacteraemia caused by E. coli or
Klebsiella spp. demonstrating non-susceptibility to third generation cephalosporins. Recruitment is
planned to occur in sites across three countries (Australia, New Zealand and Singapore). A total sample
size of 454 patients will be required to achieve 80% power to determine non-inferiority with a margin of
5%. Once randomised, definitive treatment will be for a minimum of 4 days, but up to 14 days with total
duration determined by treating clinicians. Data describing demographic information, antibiotic use, comorbid conditions, illness severity, source of infection and other risk factors will be collected. Vital signs,
white cell count, use of vasopressors and days to bacteraemia clearance will be recorded up to day 7. The
primary outcome measure will be mortality at 30 days, with secondary outcomes including days to
clinical and microbiological resolution, microbiological failure or relapse, isolation of a multi-resistant
organism or Clostridium difficile infection. Trial registration The MERINO trial is registered under the
Australian New Zealand Clinical Trials Register (ANZCTR), reference number: ACTRN12613000532707
webcite (registered 13 May 2013) and the US National Institute of Health ClinicalTrials.gov register,
reference number: NCT02176122 webcite (registered 24 June 2014).
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Meropenem versus piperacillin-tazobactam for
definitive treatment of bloodstream infections
due to ceftriaxone non-susceptible Escherichia coli
and Klebsiella spp (the MERINO trial): study
protocol for a randomised controlled trial
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Benjamin A Rogers8, Emma S McBryde9, Jason A Roberts10, Jeff Lipman10, Eugene Athan11, Sanjoy K Paul12,
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Abstract
Background: Gram-negative bacteria such as Escherichia coli or Klebsiella spp. frequently cause bloodstream infections.
There has been a worldwide increase in resistance in these species to antibiotics such as third generation cephalosporins,
largely driven by the acquisition of extended-spectrum beta-lactamase or plasmid-mediated AmpC enzymes.
Carbapenems have been considered the most effective therapy for serious infections caused by such resistant
bacteria; however, increased use creates selection pressure for carbapenem resistance, an emerging threat arising
predominantly from the dissemination of genes encoding carbapenemases. Recent retrospective data suggest that
beta-lactam/beta-lactamase inhibitor combinations, such as piperacillin-tazobactam, may be non-inferior to
carbapenems for the treatment of bloodstream infection caused by extended-spectrum beta-lactamase-producers,
if susceptible in vitro. This study aims to test this hypothesis in an effort to define carbapenem-sparing alternatives for
these infections.
Methods/Design: The study will use a multicentre randomised controlled open-label non-inferiority trial design
comparing two treatments, meropenem (standard arm) and piperacillin-tazobactam (carbapenem-sparing arm)
in adult patients with bacteraemia caused by E. coli or Klebsiella spp. demonstrating non-susceptibility to third
generation cephalosporins. Recruitment is planned to occur in sites across three countries (Australia, New Zealand
and Singapore). A total sample size of 454 patients will be required to achieve 80% power to determine non-inferiority
with a margin of 5%. Once randomised, definitive treatment will be for a minimum of 4 days, but up to 14 days with
total duration determined by treating clinicians. Data describing demographic information, antibiotic use, co-morbid
conditions, illness severity, source of infection and other risk factors will be collected. Vital signs, white cell count, use of
vasopressors and days to bacteraemia clearance will be recorded up to day 7. The primary outcome measure will be
mortality at 30 days, with secondary outcomes including days to clinical and microbiological resolution, microbiological
failure or relapse, isolation of a multi-resistant organism or Clostridium difficile infection.
(Continued on next page)

* Correspondence: p.harris@uq.edu.au
1
University of Queensland Centre for Clinical Research, Building 71/918 Royal
Brisbane & Women’s Hospital Campus, Herston, 4029 Brisbane, QLD, Australia
Full list of author information is available at the end of the article
© 2015 Harris et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.

Harris et al. Trials (2015) 16:24

Page 2 of 8

(Continued from previous page)

Trial registration: The MERINO trial is registered under the Australian New Zealand Clinical Trials Register (ANZCTR),
reference number: ACTRN12613000532707 (registered 13 May 2013) and the US National Institute of Health
ClinicalTrials.gov register, reference number: NCT02176122 (registered 24 June 2014).
Keywords: Extended-spectrum beta-lactamase, ESBL, Plasmid-AmpC, Therapy, Resistance, Beta-lactam/beta-lactamase
inhibitor, Carbapenem, Clinical trial

Background
Bloodstream infections caused by Gram-negative bacteria
such as Escherichia coli or Klebsiella spp. are commonly
encountered in clinical practice and may be associated with
significant mortality [1]. These bacteria may also acquire
genes encoding beta-lactamase enzymes that hydrolyse
essential beta-lactam antibiotics, rendering such treatment
ineffective. Isolates expressing extended-spectrum betalactamase (ESBL) or plasmid-mediated AmpC enzymes are
increasingly encountered across the world, in both
community- and hospital-onset infections [2]. ESBL- or
AmpC-producers are typically resistant to third generation
cephalosporins such as ceftriaxone, but susceptible to carbapenems [3]. These bacteria are usually multi-resistant, as
beta-lactamase genes are frequently co-located with other
resistance mechanisms, leaving few treatment options.
Bacteraemia caused by resistant Gram-negative bacteria
may carry mortality in excess of those caused by susceptible strains [4]. Thus, defining optimal treatment regimens
in these serious infections is of clinical importance. However, when selecting antimicrobial therapy, clinicians must
consider both efficacy of the chosen agent and downstream
risk such as selective pressure for further antimicrobial
resistance.
In observational studies that have been performed to
evaluate antibiotic choices for ESBL-producing Enterobacteriaceae, no agent has been shown to significantly
surpass carbapenems [5-8]. However, widespread use of
carbapenems may cause selection pressure for carbapenem
resistance [9,10]. Carbapenem-resistant Gram-negative
bacteria present a great therapeutic challenge, with susceptibility often limited to ‘last-line’ antibiotics such as colistin
or tigecycline. Some new beta-lactam antibiotics and betalactamase inhibitors, which are active against ESBL-,
AmpC- and some carbapenemase-producing organisms,
are in advanced clinical development [11,12]. However,
these antibiotics are likely to be expensive, are not yet on
the market and may best be held in reserve for infections
without therapeutic alternatives.
The susceptibility of AmpC- and ESBL-producers to
piperacillin-tazobactam is less predictable than carbapenems. By definition, ESBLs are inhibited by beta-lactamase
inhibitors such as clavulanate or tazobactam [3]. However,
E. coli or Klebsiella spp. may also produce multiple betalactamase types, some of which are resistant to inhibition

by tazobactam and may not be evident by susceptibility
testing alone. There have also been concerns that inoculum effects may overwhelm the activity of beta-lactamase
inhibition in infections with a large bacterial burden [13].
Additionally, in some cases outer membrane protein loss
may contribute to resistance to tazobactam [14]. By definition, AmpC enzymes are also not well inhibited by tazobactam [15], and plasmid-mediated AmpC expression
has been increasingly recognised as a cause of resistance
to expanded spectrum cephalosporins in Enterobacteriaceae [15]. However, despite these concerns, approximately 50% or more of ceftriaxone non-susceptible E. coli
or Klebsiella spp. remain susceptible to piperacillintazobactam [16]. Yet, until recently, lack of published
clinical experience with the use of beta-lactam/betalactamase inhibitor (BLBLI) agents for the treatment of
ESBL-producers has limited their use. As a result, carbapenems have been perceived as a superior option. In recent
years we have witnessed an alarming increase in the prevalence and global dissemination of carbapenem-resistant
Gram-negative bacteria, largely driven by the spread of
genes encoding carbapenemase enzymes, transmitted on
highly mobile plasmids [17]. Thus, defining carbapenemsparing treatment options for ESBL-producers has become
imperative to reduce the selection pressure for carbapenem
resistance [10].
No randomised controlled trials (RCTs) have yet been
performed comparing different treatment options for
third generation cephalosporin-resistant Enterobacteriaceae. The largest observational study with an analysis by
treatment outcome was published in 2012 by RodriguezBano et al. [18]. They performed a post hoc analysis of
six prospective cohorts of patients with bacteraemia due
to ESBL-producing E. coli. Two non-mutually exclusive
cohorts (empirical therapy and definitive therapy) were
constructed and analysed separately. In both cohorts,
carbapenems were not superior to BLBLI combinations,
such as piperacillin-tazobactam. Specifically, in the definitive therapy cohort, mortality rates at 30 days were
not significantly different - 9.3% for those who received
a BLBLI and 16.7% for those who received a carbapenem
(P > 0.20) [18]. A subsequent meta-analysis of all published studies examining treatment options for bacteraemia caused by ESBL-producers also concluded that
BLBLI agents were non-inferior to carbapenems for both
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definitive (relative risk (RR) 0.52, 95% confidence interval
(CI) 0.23 to 1.13) or empirical therapy (RR 0.91, 95% CI
0.66 to 1.25) with regard to all-cause mortality [6]. In contrast, mortality was lower with carbapenems when compared to non-BLBLI antibiotics (for example, quinolones)
for both definitive (RR 0.65, 95% CI 0.47 to 0.91) and empirical treatment (RR 0.50, 95% CI 0.33 to 0.77).
Both meropenem and piperacillin-tazobactam are antibiotics that have been widely used in clinical practice for
many years. They have proven efficacy in a wide range
of infectious syndromes, including severe sepsis, febrile
neutropenia, ventilator-associated pneumonia and intraabdominal sepsis. Both agents are licensed for the treatment of serious infections and are available for routine
clinical use in generic formulations. A non-inferiority study
design was selected because it is not ethically possible
to conduct a placebo-controlled trial and piperacillintazobactam is not expected to be superior to meropenem with regard to the primary end-point. Instead,
potential benefits relate to minimisation of ‘collateral
damage’ in the form of selection for carbapenem-resistant
Enterobacteriaceae.
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Setting

The trial will be conducted in several centres across
Australia, New Zealand and Singapore (see Table 1).
Intervention

Meropenem 1 gram will be administered every 8 hours
intravenously or piperacillin-tazobactam 4.5 grams administered every 6 hours intravenously. Each dose will be
given over 30 minutes. The study drug is to be administered for a minimum of 4 days and can be given for as
long as 14 days. The total duration of therapy will be determined by the treating clinician. Dose adjustment for
renal impairment will be made according to the criteria in
Table 2. Blinding will not be performed as the two antibiotics have different dosing regimens. Follow-up will be for
30 days post enrolment. Other antimicrobials active against
Gram-negative bacilli are excluded in the first 4 days
after enrolment, except that trimethoprim/sulfamethoxazole
may be continued as Pneumocystis prophylaxis.
Primary objectives
 To compare the 30-day mortality post bloodstream

Methods/Design
The trial protocol was developed by the Gram-negative
Working Group of the Australasian Society for Infectious
Disease Clinical Research Network (ASID-CRN), in accordance with the CONSORT statement extension for
‘Non-inferiority and Equivalence Trials’ [19].

infection in patients treated with piperacillintazobactam or meropenem
Secondary objectives
 To compare the time to clinical and microbiologic

resolution of infection for each regimen, defined as:
Table 1 Proposed participating sites

Hypothesis

Our hypothesis is that piperacillin-tazobactam is noninferior to meropenem for the definitive treatment of
bloodstream infections due to third generation cephalosporin non-susceptible E. coli or Klebsiella spp.

Country - State

Facility

Australia - Queensland

Royal Brisbane and Women’s Hospital
St. Andrew’s War Memorial Hospital
Brisbane Private Hospital
Princess Alexandra Hospital

Study design

The study design will be a multicentre randomised controlled non-inferiority open-label phase III trial. Both
study drugs (meropenem and piperacillin-tazobactam)
will be administered intravenously with standard dosing
regimens. The study population will be all adult patients (18 years of age or older, or 21 years or older at
Singapore sites) admitted to participating hospitals. Inclusion in the study will be determined by the presence of a
bloodstream infection with E. coli or Klebsiella spp., as
defined by at least one positive blood culture from a
peripheral blood draw, where the isolate is confirmed
to be third generation cephalosporin non-susceptible, but
susceptible to piperacillin-tazobactam and meropenem
by European Committee for Antimicrobial Susceptibility
Testing (EUCAST) standards [20].

The Mater Hospital
Australia - New South Wales

Westmead Hospital

Australia - Victoria

The Alfred Hospital

Wollongong Hospital

Monash Medical Centre
The Austin Hospital
Peter MacCallum Cancer Centre
Dandenong Hospital
Barwon Health
Australia - Western Australia

Royal Perth Hospital

New Zealand

North Shore Hospital, Auckland
Middlemore Hospital, Auckland

Singapore

National University Hospital, Singapore
Tan Tock Seng Hospital, Singapore
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Table 2 Dose adjustment for study antibiotics
Meropenem

Piperacillin-tazobactam

Creatinine clearance > 50 mL/min

No change

No change

Creatinine clearance 26 to 50 mL/min

1 g every 12 hours

4.5 g every 8 hours

Creatinine clearance 10 to 25 mL/min

500 mg every 12 hours

4.5 g every 12 hours

Creatinine clearance < 10 mL/min

500 mg every 24 hours

4.5 g every 12 hours

Haemodialysis

500 mg every 24 hours and
500 mg after each dialysis

2.25 g every 8 hours and an additional
0.75 g after each dialysis

Peritoneal dialysis

500 mg every 24 hours

2.25 g every 8 hours

Continuous-renal replacement therapy

1 g every 12 hours

4.5 g every 8 hours









number of days from randomisation to resolution of
fever (temperature > 38.0°C) and leucocytosis (white
blood cell count > 12 × 109/L) PLUS sterilisation of
blood cultures
To compare the clinical and microbiologic success
of each regimen at day 4 of the intervention, defined
as survival PLUS resolution of fever and leucocytosis
PLUS sterilisation of blood cultures. All of these
criteria will be assessed on day 4, counted from the
day of randomisation (day 1) in order to determine a
rapid response from the trial drug
To compare microbiologic resolution of infection,
defined as sterility of blood cultures collected on or
before day 4
To compare the risk of relapse with each regimen,
defined as growth of the same organism as in the
original blood culture after the end of the period of
study drug administration but before day 30
To compare the risk of superinfection with a
carbapenem or piperacillin-tazobactam- resistant
organism or Clostridium difficile, defined as growth
of a meropenem or piperacillin-tazobactam-resistant
organism from any clinical specimen collected from
day 4 of study drug administration to day 30 or a
positive C. difficile stool test (with the method of
testing used according to local laboratory protocol).
This endpoint is important since one of the purposes
of establishing an alternative to carbapenem therapy
is to reduce infections with resistant organisms or
C. difficile.

(E. coli or Klebsiella spp.) and disease severity (according
to a Pitt bacteraemia score [21] ≤ 4 or > 4; and presumed
site of infection from the urinary tract or elsewhere) (see
Figure 1).
Safety monitoring plan

A Data Monitoring and Safety Board (DMSB) will be
established, comprising two independent infectious disease physicians with statistical support provided to them
by the QCTBC. An interim analysis - including both efficacy and safety endpoints - will be performed after the
first 50 subjects have completed the 30-day study period.
The trial statistician will provide details of safety outcomes and any significant differences in primary outcomes according to treatment arm to the DMSB. The
stopping rule would be a statistically significant difference in primary outcomes between the two therapies.
Data entry and storage

A clinical database using the REDCap trial data management system has been developed with a web hosting facility. Paper case report forms (CRFs) (Additional file 1)
will be completed and uploaded to the online system to
collect all clinical and additional laboratory-related information (see Table 3). To ensure accurate transcription of
the CRF, double-data entry will be performed by a second independent researcher. Any discrepancies, missing
data or errors will be clarified by discussion with the site
principal investigator. To ensure validity, a proportion
of CRFs will be checked by the local site investigators
against clinical and laboratory records.

Randomisation

Patients will be randomly assigned to either meropenem
or piperacillin-tazobactam in a 1:1 ratio according to a
randomisation list prepared in advance for each recruiting site and stratification. Random sequence will be
generated using random permuted blocks of unequal
length. The randomisation process will be managed by the
Queensland Clinical Trials & Biostatistics Centre (QCTBC)
of The University of Queensland, and generated using an
online data management system (REDCap). Patients will
be stratified into 4 groups according to infecting species

Determination of sample size

As no randomised clinical trial has yet been conducted
in this particular field, the sample size estimation has been
derived from the retrospective study of bloodstream infection caused by ESBL-producing E. coli performed by
Rodriguez-Bano et al. [7]. The overall 30-day mortality in
their study was 16.7% in those patients who received a carbapenem (our control group). We have conducted a series
of simulations with possible variations in the observed
rates between the two treatment groups. Considering a

Harris et al. Trials (2015) 16:24

Page 5 of 8

Figure 1 Patient stratification at enrolment.

mortality rate of 17% in the control group (rounded from
the 16.7% actually observed), and a non-inferiority margin
of 5% difference in the 2 groups, we would need 280 patients in total to achieve 80% power with a 1-sided alpha
level of 0.025. This allows for 10% dropout. It is likely that
mortality rates in observational cohorts may be greater
than those in a trial with exclusion criteria. Therefore, if
the observed mortality rate in the control group was 14%
(3% lower than that seen in the observational cohort), then

under the same assumptions, we would need 454 patients
in total to achieve 80% power [22].
Actual mortality is expected to be similar in our study
population. We have performed a retrospective analysis of
92 bacteraemia episodes caused by ceftriaxone-resistant
E. coli or Klebsiella in Singapore (one of the trial sites)
over a 12-month period until May 2013, examining patients that would fulfil the MERINO trial inclusion criteria. Average mortality at 30 days was 17.4% in patients

Table 3 Data collection
Variables
Demographic data

Age, gender, ethnicity, long-term residential care status, ward location

Trial characteristics

Date of screening and enrolment, inclusion criteria and consent details, date and time of randomization

Co-morbidities and
risk factors

Charlson score, co-morbid conditions, date and type of any surgery within 14 days, use of cytotoxic chemotherapy,
immune suppressive medication, radiotherapy, biological agents (for example, monoclonal antibody therapy),
presence of intravascular devices or urinary catheters; use of ‘not for resuscitation’ order

Infection parameters

Bacteraemia acquisition status (community, healthcare-associated or hospital-acquired infection), presumed source of
infection, ICU admission, Pitt bacteraemia score, Acute Physiology and Chronic Health Evaluation (APACHE) II score (if in ICU)

Antibiotic data

From 48 hours prior to blood culture collection and up to 30 days; dose/route/frequency recorded

Clinical observations

Daily vital signs, (highest temperature, HR, RR; lowest systolic BP), lowest arterial pCO2 (if ventilated), white cell count,
use of pressors; recorded days 1 to 7; patient weight

Microbiological data

Date and time of initial blood culture, full susceptibility profile, daily blood culture results days 1 to 3; any further positive
blood cultures and species identification/resistance profile; other clinical sites growing E coli or Klebsiella,
any multidrug-resistant organism or C. difficile identified up to 30 days

Outcome data

Survival at 7 and 30 days post randomisation
Date of death or discharge
Length of hospital stay
Days to clinical and microbiological resolution
Clinical and microbiological success at day 4
Microbiological resolution or relapse
Protocol violations and adverse events
Reasons for study withdrawal

Abbreviations: BP blood pressure, HR heart rate, RR respiratory rate.
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given a carbapenem for definitive therapy. However, overall mortality for all treatment groups was lower at 8.7%,
including those receiving BLBLIs (8.3%) [23].
Statistical and analytical plans

The intention-to-treat (ITT) analysis approach, supported by the per-protocol approach, will be adopted to
make inference on the possible non-inferiority of the
treatment arm, compared to the control arm, in terms of
30-day mortality. The proportions of deaths (with 95%
CIs) in the 2 study arms will be calculated. Logistic regression with ‘treatment group’ as the only covariate will
be employed to draw inference on the possible noninferiority of the intervention treatment compared to the
control treatment. The odds ratio (with 95% CIs) will be
calculated with the meropenem arm as the reference
group. Appropriate parametric or non-parametric statistical techniques will be employed to analyse the data for
secondary aims of the study. The Mann–Whitney U-test
will be used to compare median number of days to clinical
and microbiological resolution. Logistic regression will be
used to compare odds ratios of achieving clinical and
microbiological success and microbiological resolution at
day 4, as well as the odds ratio for microbiological relapse
and superinfection with a resistant organism between each
treatment arm. All secondary analyses will be based on an
ITT population.
An analysis of primary and secondary endpoints as described above will be undertaken in a subgroup of ‘high
risk’ patients defined by a likely source of infection other
than the urinary tract or a Pitt bacteraemia score of >4.
Basic statistics in the study report will include information on missing values for all relevant study variables.
A summary of baseline patient characteristics with totals
and proportions (%) for categorical variables, and minimum, maximum, inter-quartile ranges and standard deviations for continuous variables will be presented. For
continuous study variables, box plots and Kernel density
plots will also be provided.
Protocol violations

All protocol violations occurring after randomisation
will be listed in the Clinical Study Report, tabulated by
subject and recruitment site. The final assignment of
participants to the per-protocol analysis population will
be made at a blinded protocol violation review meeting
prior to database lock.
Consent

Potential study participants will be identified on the basis
of positive blood cultures by liaison between the investigators and the clinical microbiologists. All patients who fulfill the microbiological inclusion criteria will be screened
for eligibility using a standardised screening form (see
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Additional file 2). The investigators will only approach the
patient with the agreement of the treating team. As soon
as practically possible after this discussion, the study team
representative will approach the patient at the bedside to
obtain consent. Typically this will be around 48 to 72
hours after the onset of clinical sepsis and the initial collection of blood cultures. For patients with cognitive impairment secondary to their illness (for example, intubation
and ventilation, delirium), consent will be obtained from a
legally appropriate representative (for example, spouse),
where local regulatory requirements allow recruitment of
cognitively-impaired persons to clinical trials.
Study preparation and logistics

The trial coordination centre comprises the project
management team (THB, PH and DLP) at the University
of Queensland Centre for Clinical Research in Brisbane.
Site initiation and training will be conducted by PH,
DLP and THB via web conferencing and/or site visits.
Study sites will be contacted regularly via teleconference
to discuss any issues and ensure consistent study practices across sites.
Laboratory studies

All blood culture isolates will be made available to the
central trial laboratory at the University of Queensland
Centre for Clinical Research. Susceptibility testing, including minimum inhibitory concentrations for key antimicrobials, will be repeated in the central laboratory and
interpreted according to EUCAST standards. Additional
susceptibility testing for agents not tested at the recruiting site laboratories will also be performed. Phenotypic
confirmation of ESBL or AmpC production will be performed using combination disc testing [24]. Beta-lactamase
genes will be identified and characterized. Isolates will also
be screened for carbapenemase genes and other key antimicrobial resistance determinants. Strain typing will
be determined using methods such as semi-automated
repetitive sequence-based PCR (rep-PCR) (DiversiLab;
BioMérieux, Marcy l’Étoile, France) and multi-locus sequence typing (MLST). Isolates will also be available for
whole genome sequencing.
Ethics

The protocol has been given ethical approval by the
Royal Brisbane and Women’s Hospital (ref: HREC/12/
QRBW/440), the National Healthcare Group (NHG)
Domain Specific Review Board (DSRB) in Singapore
(NHG DSRB ref: 2013/00453) and the New Zealand
Health and Disability Ethics Committee (Ref: 14/NTB/52).

Discussion
The quality and extent of evidence to help define optimal treatment for many significant bacterial infections is
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surprisingly limited. This is especially true for the treatment of resistant Gram-negative bacteraemia, despite
being a major issue in daily practice for clinicians across
many specialties. In addition to laboratory data and expert opinion, current practice is almost entirely based on
retrospective observational studies, usually conducted in
single centres with relatively small numbers of patients.
Such studies, though informative, are always prone to
bias, thus weakening the strength of conclusions drawn
for these analyses. To date, there have been no RCTs reported specifically comparing different treatment options
for ceftriaxone-resistant Enterobacteriaceae.
There is local support for the conduct of this study.
This is highlighted by a recent online survey in which
122 infectious diseases physicians in Australia and New
Zealand were asked to rank the research studies of greatest immediate clinical relevance - the proposed trial
comparing meropenem and piperacillin-tazobactam was
the highest ranked RCT in the field of antibiotic resistance in Gram-negative bacilli [25].
Antibiotic resistance is of tremendous public health
importance and has been recently described as potentially the greatest current threat to human health [26].
The MERINO trial has potential significance for two
reasons. Firstly, it addresses treatment of a common but
serious antibiotic resistance issue that is associated with
10 to 20% mortality [5,18]. Secondly, proving that a
carbapenem-sparing antibiotic regimen is non-inferior to
a carbapenem will help encourage use of alternatives to
carbapenems. Carbapenem resistance is the ‘end-game’
with respect to antibiotic resistance as it eliminates one
of our most important antibiotic options and leaves few
effective alternative treatments. Evidenced-based strategies to support the clinical management of resistant infections that consider both efficacy and the potential for
‘collateral damage’ of treatment options are therefore urgently needed.

Trial status
A pilot study based on this protocol has commenced recruitment in both Singapore and Australia in February
2014. The remaining study sites are scheduled to begin
enrolment later during 2014 once local regulatory requirements have been completed. It is planned for the
pilot phase to be extended to a definitive trial in early
2015. It is aimed that recruitment for the definitive study
will be completed by late 2016. Data from the pilot
phase will be included in the definitive study analysis.
Additional files
Additional file 1: MERINO Trial Clinical Record Form.
Additional file 2: MERINO Trials Initial Screening Form.
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